Recon: Metsera plunges after accepting Pfizer’s $10B offer; Eli Lilly partners with MeiraGTx's for eye disease gene therapy

• Is the White House’s deal with pharma on GLP-1 drugs a game changer? (STAT)
• Fate of ACA subsidies still clouded after deal to reopen the government (STAT)
• US FDA Begins ‘Competitive Search’ For New Drugs Center Director (Pink Sheet)
• Metsera falls after accepting up to $10 billion offer from Pfizer (Reuters) (Endpoints)
• Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease (Reuters) (Endpoints)
• PDUFA VIII: FDA Pilot Programs, Workforce Challenges Could Shape Renewal Debate (Pink Sheet)
• Makary And Oz Tout Successes At Their Respective Agencies, Say They Are Breaking Down Walls (MedTech Insight)
• Novartis opens new plant in California to make cancer drugs (Reuters)

• Canada loses measles elimination status — as does the entire Americas region (STAT)
• German online drug retailer Redcare Pharmacy names Hendrik Krampe as CFO (Reuters)
• Germany's Siemens to set out plan for $41 billion Healthineers stake (Reuters)
• India Sets Sights On ‘First-In-World’ Medtech Innovation (MedTech Insight)
• Novo Nordisk, Emcure to launch weight-loss drug under new brand in India (Reuters)
• Under Pressure: How To Safeguard The EU Responsible Person (MedTech Insight)

• Weight-loss drug developers line up to tap lucrative market as competition heats up (Reuters)
• Roche reports two Phase 3 wins for its BTK inhibitor in multiple sclerosis (Endpoints)
• Merck’s pill to reduce cholesterol on top of statins matches results from injectables (STAT)
• How Regulatory Horizon Scanning Works In The EU, UK & Switzerland (Pink Sheet)
• US FDA ANDA Priority Pilot ‘Practically Unusable’ Without Tweaks, AAM CEO Says (Pink Sheet)
• Ex-Lilly Diabetes leaders hunt for new obesity drugs at VC firm aimed at 'advancing the science' (Endpoints)
• Catalent lays off more gene therapy workers in Baltimore (Endpoints)
• Cogent soars on back of Phase 3 success in stromal tumors (Endpoints)
• AnaptysBio reports Phase 2 fail in ulcerative colitis; Lyell's CAR-T licensing deal (Endpoints)
• CRISPR Therapeutics’ gene editing therapy halves cholesterol and triglycerides in early trial (Endpoints)
• Ionis claims curative potential for Tryngolza in severe triglyceride disease (Endpoints)

• Microsoft launches 'superintelligence' team targeting medical diagnosis to start (Reuters)
• Exclusive: AI biotech Iambic raises $100M, expects three drugs in clinic in 2026 (Endpoints)
• MMI tackles Alzheimer’s; SS Innovations advances telesurgery (MedTech Dive)
• Synchron raises $200M to prepare for brain computer interface launch (MedTech Dive)
• Olympus to cut 2,000 jobs in endoscopy reorganization (MedTech Dive)

• Does coffee mix with AFib, and other new data from heart meeting (STAT)
• At AHA meeting, CRISPR data gleamed but ‘food as medicine’ spoke to the now (STAT)

• It’s time to fundamentally rethink how America pays for health care (STAT)
• Trump renews a Republican battle cry: Repeal Obamacare (STAT)
• Ninth Circuit Sends USDA’s Agricultural Marketing Service (“AMS”) Back to Drawing Board on Some Aspects of the BE Labeling Rule (FDA Law Blog)